Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 3/20 | 0.30 |
| ▸ | CTSD | P07339 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29955816 | 1.00 | ENPP2 (0.32) | ENPP2PARP1PRMT5WDR77EGLN1 | |
| SCHEMBL29952025 | 0.90 | PRMT5 (0.39) | PRMT5WDR77CYP2A6BACE1CTSD | |
| SCHEMBL29957892 | 0.81 | GRM5 (0.31) | ENPP2GRM5 | |
| SCHEMBL9948434 | 0.80 | GRM5 (0.35) | ENPP2CYP2A6GRM5 | |
| SCHEMBL5742874 | 0.79 | GRM5 (0.38) | PARP1PRMT5WDR77EGLN1CYP2A6 | |
| SCHEMBL248711 | 0.76 | ENPP2 (0.52) | ENPP2 | |
| SCHEMBL15957833 | 0.74 | GRM5 (0.40) | PRMT5WDR77CYP2A6GRM5 | |
| SCHEMBL2381674 | 0.74 | — | — | |
| SCHEMBL28967087 | 0.73 | ENPP2 (0.36) | ENPP2 | |
| SCHEMBL21518938 | 0.73 | GRM5 (0.38) | PARP1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3064494-A1 | A PROCESS FOR THE PREPARATION OF A CAMSYLATE SALT ((1S)-(+)-10 CAMPHORSULFONIC ACID) OF (1R,1'R,4R)- 4-METHOXY-5\"-METHYL-6'-[5-(PROP-1-YN-1-YL)PYRIDIN- 3-YL]-3'H-DISPIRO[CYCLOHEXANE-1,2'-INDEN-1'2'-IMIDAZOLE]-4\"-AMINE | AstraZeneca AB (SE) | 2016-09-07 | — | — | EP | claimed |
| US-10548882-B2 | Camsylate salt | ASTRAZENECA AB (SE) | 2020-02-04 | — | — | US | disclosed |
| EP-3176172-B1 | SPIROIMIDAZOLE COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2020-01-29 | — | — | EP | disclosed |
| EP-3176172-B1 | SPIROIMIDAZOLE COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2020-01-29 | — | — | EP | disclosed |
| EP-2961749-B1 | PERFLUORINATED 5,6-DIHYDRO-4H-1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC (US) | 2019-10-09 | — | — | EP | disclosed |
| US-20190262327-A1 | COMBINATION OF A BACE INHIBITOR AND AN ANTIBODY OR ANTIGEN-BINDING FRAGMENT FOR THE TREATMENT OF A DISORDER ASSOCIATED WITH THE ACCUMULATION OF AMYLOID BETA | ASTRAZENECA AB (SE) | 2019-08-29 | — | — | US | disclosed |
| US-10231967-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2019-03-19 | — | — | US | disclosed |
| US-10231967-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2019-03-19 | — | — | US | disclosed |
| EP-1891021-B1 | ASPARTYL PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2019-01-23 | — | — | EP | disclosed |
| US-10053453-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2018-08-21 | — | — | US | disclosed |
| WO-2011002409-A1 | 5H-PYRROLO[3,4-£>]PYRAZIN-7-AMINE DERIVATIVES INHIBITORS OF BETA-SECRETASE | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011002407-A1 | NOVEL COMPOUNDS FOR TREATMENT OF NEURODEGENERATION ASSOCIATED WITH DISEASES, SUCH AS ALZHEIMER'S DISEASE OR DEMENTIA | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011002407-A1 | NOVEL COMPOUNDS FOR TREATMENT OF NEURODEGENERATION ASSOCIATED WITH DISEASES, SUCH AS ALZHEIMER'S DISEASE OR DEMENTIA | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | WO | disclosed |
| US-7759353-B2 | Substituted spiro iminopyrimidinones as aspartyl protease inhibitors, compositions, and methods of treatment | SCHERING CORPORATION (US) | 2010-07-20 | — | — | US | disclosed |
| EP-1891021-A1 | ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION (US) | 2008-02-27 | — | — | EP | disclosed |
| US-20070287692-A1 | ASPARTYL PROTEASE INHIBITORS | MERCK SHARP & DOHME LLC | 2007-12-13 | — | — | US | disclosed |
| US-20070060575-A1 | Aspartyl protease inhibitors | MERCK SHARP & DOHME LLC | 2007-03-15 | — | — | US | disclosed |
| US-20070060575-A1 | Aspartyl protease inhibitors | MERCK SHARP & DOHME LLC | 2007-03-15 | — | — | US | disclosed |
| WO-2006138217-A1 | ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION (US) | 2006-12-28 | — | — | WO | disclosed |
| US-20060287294-A1 | Aspartyl protease inhibitors | MERCK SHARP & DOHME LLC | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10548882-B2 | Camsylate salt | PSEN1, PSEN2, MAPT | ENPP2 1506/4885PARP1 224/4885PRMT5 2561/4885 |
| US-20070060575-A1 | Aspartyl protease inhibitors | CHRM2, BACE1, CHRM1 | ENPP2 2244/4885PARP1 2232/4885PRMT5 654/4885 |
| US-20060287294-A1 | Aspartyl protease inhibitors | CHRM1, BACE1, CHRM2 | ENPP2 1620/4885PARP1 2021/4885PRMT5 528/4885 |
| US-10231967-B2 | Compounds and their use as BACE inhibitors | BACE1, BACE2, APP | ENPP2 351/4885PARP1 174/4885PRMT5 2942/4885 |
| US-20070287692-A1 | ASPARTYL PROTEASE INHIBITORS | CHRM1, CHRM2, BACE1 | ENPP2 1211/4885PARP1 1947/4885PRMT5 538/4885 |
| US-20190262327-A1 | COMBINATION OF A BACE INHIBITOR AND AN ANTIBODY OR ANTIGEN-BINDING FRAGMENT FOR THE TREATMENT OF A DISORDER ASSOCIATED WITH THE ACCUMULATION OF AMYLOID BETA | BACE2, BACE1, APP | ENPP2 509/4885PARP1 1669/4885PRMT5 1042/4885 |
| US-10053453-B2 | Compounds and their use as BACE inhibitors | BACE1, BACE2, APP | ENPP2 586/4885PARP1 569/4885PRMT5 3777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.